These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor. Hata K; Fujiwaki R; Nakayama K; Maede Y; Fukumoto M; Miyazaki K Anticancer Res; 2000; 20(5C):3941-9. PubMed ID: 11268481 [TBL] [Abstract][Full Text] [Related]
9. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077 [TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Gadducci A; Viacava P; Cosio S; Cecchetti D; Fanelli G; Fanucchi A; Teti G; Genazzani AR Anticancer Res; 2003; 23(3C):3001-8. PubMed ID: 12926153 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Brustmann H Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105 [TBL] [Abstract][Full Text] [Related]
13. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Fine BA; Valente PT; Feinstein GI; Dey T Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438 [TBL] [Abstract][Full Text] [Related]
14. [Expression of vascular endothelial growth factor and microvessel density in ovarian tumor]. Qi SY Ai Zheng; 2003 Mar; 22(3):320-3. PubMed ID: 12654197 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306 [TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Yamamoto S; Konishi I; Mandai M; Kuroda H; Komatsu T; Nanbu K; Sakahara H; Mori T Br J Cancer; 1997; 76(9):1221-7. PubMed ID: 9365173 [TBL] [Abstract][Full Text] [Related]
20. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]